A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism

Entera Bio

Status and phase

Completed

Phase 2

Conditions

Hypoparathyroidism

Treatments

Drug: EnteraBio's Oral Parathyroid Hormone (1-34)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02152228

ENT-03-2014

Details and patient eligibility

About

This is an observational, international, open label, pilot study to evaluate the safety, tolerability and efficacy of an oral PTH (1-34) preparation produced by Entera Bio in adult hypoparathyroid volunteers.

Enrollment

20 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of primary hypoparathyroidism for more than 1 year.
Currently taking >1.0 grams of Calcium/day with a correlate alpha D3 dose.
25(OH)D levels ≥ 20 ng/ml.
Signed informed consent.
BMI 18 - 30 kg/m2, inclusive.
Full blood count should be within the reference range as per WHO criteria. Minor abnormalities will be assessed by the Principle Investigator and after discussion with sponsor patients may still be entered if these are felt to be of "no clinical importance". Abnormalities due to hypoparathyroidism related are acceptable and will not constitute exclusion.
Patients with significant liver function impairment (liver enzymes above x3 the upper limit of normal range as per WHO criteria) will be excluded.
Subjects able to adhere to the visit schedule and protocol requirements.

Exclusion criteria

Haemoglobin <12 g/dL (females)/ <13gm/dL (males) [lower limit of reference range 12-15 & 13-17]
Impaired renal function
impaired liver function; ALT >38 international units per liter (IU/L), or ALP>125 IU/L
Significant drug or alcohol abuse as assessed by the Principal Investigator
Allergy to soy bean products
Presence of kidney or urinary tract stones
Concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
Treatment with any investigational product within the last 30 days, enrollment or intention to enroll in any active study involving the use of investigational devices or drugs.
Presence of any other condition or circumstance that, in the judgment of the Investigator, might increase the risk to the patient or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
Active infections
Pregnancy or suspected pregnancy. Female subjects must have a negative serum pregnancy test at screening and be willing and able to use a medically acceptable method of birth control (reliable use of oral contraceptive, non-hormonal intrauterine device with condom, or diaphragm with condom, or condom with spermicide) from the screening visit through the study termination visit or declare that they are abstaining from sexual intercourse from the screening visit through the study termination visit or are surgically sterile (have undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.